Clinical trials: Anticoagulant Drugs
Liver Cirrhosis, Portal Hypertension
Anticoagulation Therapy After Splenectomy in Cirrhosis Patient
1. Inclusion and Exclusion Criteria Inclusion criteria: Inpatients who received laparotomy or laparoscopic splenectomy according to clinical, B-ultrasound scan, CT or MRI diagnosis of cirrhosis and portal hypertension.
- Conditions
- Liver Cirrhosis, Portal Hypertension, Anticoagulant-induced Bleeding, Thrombosis
- Trial name
- ATASICP (NCT04397289)
- Testing
- Heparin and Rivaroxaban
- Where
- China
- Volunteers
- 70 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Recurrent Pregnancy Loss, Antiphospholipid Antibody Syndrome
Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT
To compare the livebirth rate of women with recurrent pregnancy loss and autoantibodies randomized to either low molecular weight heparin plus aspirin versus aspirin alone.
- Trial name
- HepASA (NCT00564174)
- Testing
- Low molecular weight heparin and low dose aspirin, Low dose aspirin
- Where
- 2 sites in Canada
- Volunteers
- 88 people
- Sponsor
- Mount Sinai Hospital, Canada
Stroke, Ischemic Stroke
Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation
Patients who have recently had an ischemic stroke with no clear cause might have undetected atrial fibrillation (AF) that isn't caught during their initial hospital stay.
- Conditions
- Stroke, Ischemic Stroke, Cerebral Infarction, Atrial Fibrillation
- Trial name
- SPICAF (NCT06486792)
- Testing
- Apixaban, Aspirin
- Where
- France
- Volunteers
- 1,148 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Heart Failure, Atrial Fibrillation
The First Russian Observational Survey of Heart Failure Patients With Atrial Fibrillation
The purpose of this study is to evaluate the management of chronic heart failure patients with atrial fibrillation, to collect data on compliance with clinical guidelines and the prevalence of long-term anticoagulant…
- Trial name
- RIF-CHF (NCT02790801)
- Testing
- observation
- Where
- Russia
- Volunteers
- 1,000 people
- Sponsor
- Federal State Budgetary Scientific Institution, Research Institute of Cardiology
Cancer-associated Thrombosis
Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis in Thai Population
The goal of this observational study is to learn about the long-term efficacy and safety of extended anticoagulant treatment in patients with cancer associated thrombosis.
- Trial name
- NCT07388056
- Testing
- Anticoagulant
- Volunteers
- 169 people
- Sponsor
- Thammasat University
Anticoagulant Therapy
In Vitro Diagnostic Test for DOAC in Urine
This trial is conducted to assess the performance and handling of the in vitro diagnostic (IVD) device for oral direct factor Xa and thrombin inhibitors from urine samples of patients on treatment with direct oral anticoagulants…
- Trial name
- PADOASU (NCT03182829)
- Testing
- DOAC Dipstick
- Where
- 18 sites in Germany
- Volunteers
- 880 people
- Sponsor
- Doasense GmbH
Atrial Fibrillation
High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns, and safety and effectiveness outcomes in patients with NVAF…
- Trial name
- HELIOS-AF (NCT05038228)
- Testing
- Apixaban, Rivaroxaban, Dabigatran
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Pfizer
Venous Thromboembolism
Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis
The purpose of this study is to evaluate whether low-molecular-weight heparin could be equally or more effective than oral anticoagulation in the long-term treatment of deep venous thrombosis.
- Trial name
- NCT00689520
- Testing
- tinzaparin, acenocoumarol
- Where
- 2 sites in Spain
- Volunteers
- 241 people
- Sponsor
- Hospital Universitari de Bellvitge
Deep Venous Thrombosis
Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery
Extended Venous Thromboemboism Prophylaxis After Bariatric Surgeries: A Comparison Of Low Molecular Weight Heparin With Direct Oral Anticoagulant
- Trial name
- NCT06913595
- Testing
- Direct Oral Anticoagulant., Low Molecular Weight Heparine
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Cairo University
Covid-19, Thromboembolic Events
Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients
The aims of the study are to to associate anticoagulation (AC) regime with outcome in critically ill patients with Covid-19. This will be done by describe baseline characteristics and comorbidities before hospital admission…
- Conditions
- Covid-19, Thromboembolic Events, Bleeding
- Trial name
- NCT04412304
- Testing
- Dose of Tinzaparin or Dalteparin
- Where
- Sweden
- Volunteers
- 166 people
- Sponsor
- Karolinska Institutet
Aortic Valve Disease
DIrect Oral Anticoagulation and Bioprothesis Aortic Valve
DIAMOND study is a national, multicentre, randomized, parallel-group, open label study in patients (aged ≥18 years) with aortic bioprosthesis (excluding TAVI) at least 7 days after cardiac surgery.
- Trial name
- DIAMOND (NCT05687448)
- Testing
- Apixaban 5 MG Oral Tablet, Aspirin 75 to 100mg once a day
- Where
- France
- Volunteers
- 1,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bleeding, End Stage Renal Disease
Pilot Bleeding Study: Risk and Protective Factors Associated With Bleeding in the Hemodialysis Population
This study is examining the risk and protective factors associated with bleeding in the hemodialysis population.
- Trial name
- NCT00182117
- Where
- Canada
- Volunteers
- 490 people
- Sponsor
- Hamilton Health Sciences Corporation
Venous Thromboembolism
Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics
The purpose of this study is to evaluate whether the effect of the two new anticoagulants, Dabigatran and Rivaroxaban, can be reversed by non-specific and specific inhibitors.
- Trial name
- REVNEWANTICO (NCT01210755)
- Testing
- Rivaroxaban, Dabigatran, Dabigatran; Rivaroxaban
- Where
- France
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Healthy Volunteers
Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers
Background: Rivaroxaban and apixaban are blood thinners. People with HIV may need to take them to treat or prevent blood clots. The anti-HIV drug darunavir (DRV) can increase the amount of these blood thinners in the body.
- Trial name
- NCT03864406
- Testing
- Cobicistat, Darunavir/Cobicistat, Rivaroxaban
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Cardiac Surgery
Benefits of a Comprehensive Patient Education on Oral Anticoagulant Compared to Conventional Hospital Education
To meet the wishes of the Ministry of Health, the division of Cardiology University Hospital of Clermont Ferrand, combining the cardiology and cardiac surgery department, has developed since January 2009, a therapeutic education…
- Trial name
- EDUCA (NCT01699282)
- Testing
- VKA (antivitamin K) education, conventional hospital education
- Where
- France
- Volunteers
- 186 people
- Sponsor
- University Hospital, Clermont-Ferrand
Pulmonary Embolism, Embolism
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
The clinical significance of pulmonary embolism (PE) limited to the subsegmental pulmonary arteries, so called isolated subsegmental pulmonary embolism (SSPE), remains controversial.
- Conditions
- Pulmonary Embolism, Embolism, Embolism and Thrombosis, Lung Diseases
- Trial name
- SAFE-SSPE (NCT04263038)
- Testing
- Rivaroxaban
- Where
- 40 sites in Belgium, Canada and 3 more
- Volunteers
- 276 people
- Sponsor
- Drahomir Aujesky
Cerebrovascular Stroke, Intracranial Hemorrhages
Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban
This study was aimed at patients with newly diagnosed stroke / TIA associated with nonvalvular atrial fibrillation. We will observe the effect of early using rivaroxaban anticoagulation on hemorrhagic transformation, and explore…
- Conditions
- Cerebrovascular Stroke, Intracranial Hemorrhages, Anticoagulant, Matrix Metalloproteinases
- Trial name
- NCT03772457
- Testing
- Rivaroxaban
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Venous Thromboembolism
A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total knee arthroplasty.
- Trial name
- NCT01181102
- Testing
- edoxaban, enoxaparin sodium
- Where
- 3 sites in Japan, Taiwan
- Volunteers
- 716 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Pulmonary Embolism, Venous Thromboembolism
Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients
There's no unified recommendation in clinical practice regarding adjusting dosages for different patient types, especially when adverse events occur.
- Conditions
- Pulmonary Embolism, Venous Thromboembolism, Anticoagulant-induced Bleeding
- Trial name
- NCT06194617
- Testing
- Direct oral anticoagulant
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Recurrent Venous Thromboembolism, Idiopathic Deep Vein Thrombosis
Prolonged Anticoagulation After a First Episod of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP)
In a French multicenter double blind randomized controlled trial, the main objective is to demonstrate that, after 6 months of oral anticoagulation for a first episode of idiopathic proximal deep vein thrombosis, 18 months of…
- Trial name
- PADIS TVP (NCT00740493)
- Testing
- warfarin
- Where
- 14 sites in France
- Volunteers
- 104 people
- Sponsor
- University Hospital, Brest